Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically treatable stage III non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7171-7171
Author(s):  
N. Villanueva ◽  
E. Esteban ◽  
J. Fra ◽  
J. De Sande ◽  
B. Mareque ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Randomised Study ◽  
Preliminary Results

scholarly journals Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer

2010 ◽  
Vol 139 (6) ◽  
pp. 1424-1430 ◽  
Author(s):  
Walter Weder ◽  
Stéphane Collaud ◽  
Wilfried E.E. Eberhardt ◽  
Sven Hillinger ◽  
Stefan Welter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Treatment Option ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Valuable Treatment

scholarly journals Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Caroline Y. Chen ◽  
Charlene M. Fares ◽  
Daniel Sanghoon Shin
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
African American Patient ◽  
Small Cell Lung ◽  
Stage Iiia

Abstract Introduction Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC). Case presentation Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadjuvant setting with concurrent radiation, followed by resection. The patient remains disease-free 4 months after surgery. Conclusion This case report suggests that osimertinib may be effective as neoadjuvant therapy in resectable stage III disease. Additionally, we provide a summary of previous case reports and ongoing clinical trials for neoadjuvant EGFR inhibition in stage III NSCLC patients.

Sign in / Sign up

Export Citation Format

Share Document